NA
PACB icon

NewEdge Advisors’s Pacific Biosciences PACB Stock Holding History

NewEdge Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-700
Closed -$2.63K – 3951
2024
Q1 		$2.63K Hold
700
– – ﹤0.01% 3317
2023
Q4 		$6.87K Hold
700
– – ﹤0.01% 3003
2023
Q3 		$5.84K Hold
700
– – ﹤0.01% 2755
2023
Q2 		$9.31K Sell
700
-544
-44% -$6.61K ﹤0.01% 2618
2023
Q1 		$14.4K Sell
1,244
-966
-44% -$9.6K ﹤0.01% 2449
2022
Q4 		$7.91K Buy
+2,210
New +$19K ﹤0.01% 2445

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's PACB Position: Q2 2024 in Review

NewEdge Advisors sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 700 shares — an estimated $2.63K sold.

NewEdge Advisors first reported a position in PACB in Q4 2022 and held it in 6 quarters. The position peaked at $14.4K in Q1 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • NewEdge Advisors reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • NewEdge Advisors sold 700 Pacific Biosciences shares in Q2 2024, an estimated $2.63K.
  • NewEdge Advisors first reported a position in Pacific Biosciences in Q4 2022 and held it in 6 quarters.
  • NewEdge Advisors's Pacific Biosciences position peaked at $14.4K in Q1 2023.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on NewEdge Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.